Vera Therapeutics (VERA) Projected to Post Quarterly Earnings on Thursday

Key Points

• Vera Therapeutics is set to release its Q2 2025 earnings before the market opens on August 14th, with analysts estimating a loss of ($0.82) per share.
• In the last earnings report on August 5th, Vera missed expectations, reporting a loss of ($1.20) EPS, compared to the previous year's loss of ($0.62) EPS.
• The company's stock has a market cap of $1.23 billion and has seen significant institutional interest, with 99.21% of the stock owned by institutional investors and hedge funds.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.82) per share for the quarter.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($1.20) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.38). During the same quarter in the previous year, the business posted ($0.62) earnings per share. On average, analysts expect Vera Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Vera Therapeutics Stock Performance

VERA traded up $0.07 during trading hours on Friday, hitting $19.79. The company's stock had a trading volume of 1,047,828 shares, compared to its average volume of 1,078,886. Vera Therapeutics has a fifty-two week low of $18.53 and a fifty-two week high of $51.61. The company has a current ratio of 17.03, a quick ratio of 27.68 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $1.26 billion, a PE ratio of -5.53 and a beta of 1.17. The company has a 50-day simple moving average of $22.97 and a 200 day simple moving average of $25.08.

Insider Activity

In related news, Director Patrick G. Enright bought 209,393 shares of the firm's stock in a transaction that occurred on Monday, June 23rd. The shares were acquired at an average cost of $20.87 per share, for a total transaction of $4,370,031.91. Following the acquisition, the director directly owned 3,569,522 shares of the company's stock, valued at $74,495,924.14. The trade was a 6.23% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 16.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Vera Therapeutics

A number of hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Vera Therapeutics by 7.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company's stock worth $753,000 after acquiring an additional 2,210 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Vera Therapeutics by 22.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company's stock valued at $2,354,000 after buying an additional 17,907 shares in the last quarter. Finally, Jane Street Group LLC grew its holdings in shares of Vera Therapeutics by 297.1% during the first quarter. Jane Street Group LLC now owns 41,578 shares of the company's stock valued at $999,000 after buying an additional 62,678 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

VERA has been the topic of several research analyst reports. JPMorgan Chase & Co. lowered their price target on Vera Therapeutics from $56.00 to $53.00 and set an "overweight" rating on the stock in a research report on Thursday. Wolfe Research reiterated a "peer perform" rating on shares of Vera Therapeutics in a research report on Monday, August 4th. Wedbush lowered their price target on Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Cantor Fitzgerald lowered their price target on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Finally, Guggenheim reiterated a "buy" rating on shares of Vera Therapeutics in a research report on Tuesday, June 3rd. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Vera Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $63.00.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.